Clinical Trials HR Nurses Trials 
The Pharma Data
MARCH 25, 2021
These findings represent the first comprehensive comparative effectiveness analysis of survival outcomes for a CDK 4/6 inhibitor in routine clinical practice and were published online in Breast Cancer Research. months with letrozole alone (HR 0.58: 95% CI, 0.49 months among patients in the letrozole group (HR 0.66: 95% CI, 0.53
Triage Cancer
APRIL 27, 2021
Accessing clinical trials. FREE continuing education credits/contact hours for social workers and nurses, 7 FREE continuing education credits for patient advocates, and 6 FREE PDCs for HR professionals. Understanding health insurance options, picking a plan, using your coverage, and appealing denials.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 29, 2020
As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes. The primary clinical objective of this initial analysis was to determine if there was sufficient efficacy in these patients to warrant continuing the trial (i.e.,
The Pharma Data
FEBRUARY 8, 2021
IBRANCE is indicated for the treatment of adult patients with HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women or in men; or with fulvestrant in patients with disease progression following endocrine therapy. 2,3 In the U.S.,
Pfizer
JANUARY 27, 2023
telehealth, in-person visit) with a physician, advanced practice registered nurse, or physician assistant licensed or authorized under state law to prescribe drugs, if any of the following apply: Sufficient information is not available to assess renal and hepatic function. No dosage adjustment is needed in patients with mild renal impairment.
The Pharma Data
JUNE 18, 2021
“The CLL14 trial results observed after four years of follow-up with treatment of venetoclax plus obinutuzumab show that these patients can experience long-lasting responses without disease progression, years after stopping treatment,” said Mohamed Zaki , M.D., months; hazard ratio [HR] 0.33 [95% CI 0.25-0.45]);
Pfizer
DECEMBER 13, 2022
PAXLOVID may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs. The state-licensed pharmacist should refer an individual patient for clinical evaluation (e.g.,
Expert insights. Personalized for you.
52 
Let's personalize your content